TruScreen has submitted 3 proposals developed in partnership with leading global and regional health organisations, to deploy TruScreen's portable AI-enabled opto-electronic cervical screening technology across 14 high-burden countries in Africa, AsiaPacific, and Latin America with an addressable market of 1 billion women of screening age.

Mr Christopher Horn has informed the Company of his intention to retire as a non-executive director following the filing of the Company’s Preliminary Final results, expected to be on or around 31 May 2026.

An independent clinical study comparing TruScreen with Thinprep cytology test (TCT), and in combination with high-risk human papillomavirus (hr-HPV) testing, has been published and peer-reviewed in Journal of Sichuan University, confirming superiority of TruScreen + hr-HPV co-testing.

Results of the world's largest ever (n=14,982) study of opto-electronic cervical cancer screening, conducted by Chinese Obstetricians and Gynaecologists Association (COGA), have been published validating TruScreen as a superior primary cervical cancer screening tool over Liquid Based Cytology (LBC) and high-risk Human Papillomavirus (hrHPV) testing.

TruScreen Group Limited is pleased to provide an update on activities in key markets: Uzbekistan, Zimbabwe, Central Asia, Europe and China.

Leading Chinese medical publication Family Doctor confirms TruScreen’s efficacy as a cervical cancer screening tool for pregnant women, in a 2,000-patient study conducted at Guilin People’s Hospital.

TruScreen has authorised it's Indian distributor, Renovate Biologicals Pvt Ltd, to investigate commercial and market opportunities in the Middle East and Western Europe from 1 January 2026.

TruScreen has appointed Johannesburg distributor AIR to distribute its AI enabled TruScreen cervical cancer screening system in South Africa. This is a key market for TruScreen’s African strategy that will grow TruScreen’s African distribution reach to 30 million women of screening age.

View TruScreen’s Annual Shareholder Meeting presentation, delivered today by Martin Dillon, CEO.

An update on the implementation of our strategy to engage with Ministries of Health, Non-Government Organizations (NGO’s) and private foundations funding public screening programs in emerging markets.

The Share Purchase Plan announced on 29 May 2025 closed oversubscribed raising ~NZ$1.67 million (~83 million shares at NZ$0.02).

View TruScreen’s Annual Report 2025.

Truscreen is pleased to advise that the Company has received firm commitments from both new and existing investors for an initial Placement of 107,034,091 shares at NZ$0.022/A$0.02 each to raise NZ$2,354,750, before costs.

Following a year of significant progress growing our geographic distribution capability (India and Indonesia, among others) and product suite (Dalton Bio HPV IVD products), TruScreen is seeking approximately NZ$3m through Placement, Share Purchase Plan and Options to fund further growth.

TruScreen is pleased to announce that an Agreement has been signed with Hangzhou Dalton Bioscience Limited (“DaltonBio”), for TruScreen to distribute DaltonBio’s HPV-related In Vitro Diagnostics (“IVD”) products in India.

Truscreen Group Limited (NZX/ASX: TRU) (the Company) has released its preliminary unaudited financial results for the year ended 31 March 2025.

Published Saudi Arabia study confirms TruScreen’s high sensitivity and specificity compared to pap smear.

TruScreen re-enters India and appoints Renovate Biologicals Pvt Ltd to distribute its AI enabled TruScreen cervical cancer screening system in India.

Marty Dillon, TruScreen CEO, is presenting the company’s innovative AI enabled cervical cancer screening technology at the Singapore Healthcare Day Forum.

TruScreen Group Limited (NZX/ASX:TRU) is pleased to provide an update of its key markets and target markets.